The strategic alliance between BioInvent International AB and ThromboGenics NV received a double whammy, as the two companies halted development of an anticoagulation antibody, TB-402, following unfavorable data from a Phase IIb head-to-head trial against Xarelto (rivaroxaban), while Roche Holding AG decided to exit a three-way alliance to develop an angiogenesis inhibitor, TB-403. Read More
A third tranche of $23 million brings PhaseBio Pharmaceuticals Inc.'s Series B financing total to $48.4 million. The disbursement was triggered by completion of a Phase I/IIa trial of Glymera in Type II diabetes. Read More
CHICAGO – On the last day of the 2012 American Society of Clinical Oncology (ASCO) meeting, the crowds had thinned enough so that the convention center staff no longer had an individual on duty in the East Hall whose sole task it was to exhort conventioneers to "stay right by order of the fire marshal." Read More
Advaxis Inc. reported positive preliminary results from a Phase II trial of its human papillomavirus (HPV) immunotherapy product, ADXS-HPV, at the American Society of Clinical Oncology meeting in Chicago this week. Read More
• ERYtech Pharma, of Lyon, France, received more than $8.65 million from OSEO's Strategic Industrial Innovation program to lead the eight-year TEDAC project, which is focused on developing enzymes targeting chemo- and radio-resistant cancers, as well as tools to identify responders and enable personalized treatment. Read More
• Durect Corp., of Cupertino, Calif., and Pain Therapeutics Inc., of Austin, Texas, were issued four patents relating to their Oradur technology, Remoxy (oxycodone) Extended-Release Capsules CII and other Oradur-based opioids. Read More
• Aeterna Zentaris Inc., of Quebec City, said Phase I results of its oral cancer compound, perifosine, in multiple myeloma, were published in the online issue of the British Journal of Haematology. The article reviews the safety profile and clinical activity of the PI3K/Akt pathway inhibitor when combined with Revlimid (lenalidomide, Celgene Corp.) and dexamethasone in relapsed and relapsed/refractory multiple myeloma. Perifosine is partnered with Keryx Biopharmaceuticals Inc., of New York. Read More
